Advertisement
Research Article

Differential Ligand Binding to a Human Cytomegalovirus Chemokine Receptor Determines Cell Type–Specific Motility

  • Jennifer Vomaske,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Ryan M. Melnychuk,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Patricia P. Smith,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Joshua Powell,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Laurel Hall,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Victor DeFilippis,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Klaus Früh,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Martine Smit,

    Affiliation: Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Chemistry, Amsterdam, The Netherlands

    X
  • David D. Schlaepfer,

    Affiliation: Department of Immunology, The Scripps Research Institute, La Jolla, California, United States of America

    X
  • Jay A. Nelson,

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Daniel N. Streblow mail

    streblow@ohsu.edu

    Affiliation: Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America

    X
  • Published: February 20, 2009
  • DOI: 10.1371/journal.ppat.1000304

About the Authors

Jennifer Vomaske, Ryan M. Melnychuk, Patricia P. Smith, Joshua Powell, Laurel Hall, Victor DeFilippis, Klaus Früh, Jay A. Nelson, Daniel N. Streblow
Department of Molecular Microbiology and Immunology and The Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, United States of America
David D. Schlaepfer
Department of Immunology, The Scripps Research Institute, La Jolla, California, United States of America
Martine Smit
Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Chemistry, Amsterdam, The Netherlands

Corresponding Author

Email: streblow@ohsu.edu

Competing Interests

OHSU and investigators D. Streblow and J. Nelson have a financial interest in Virogenomics, Inc., a company that has rights to US28. The potential conflict of interest has been reviewed and managed by the OHSU Conflict of Interest in Research Committee.

Author Contributions

Conceived and designed the experiments: JEV KF JAN DNS. Performed the experiments: JEV RMM JDP VD. Analyzed the data: JEV VD. Contributed reagents/materials/analysis tools: PPS JDP LH VD KF MS DDS. Wrote the paper: JEV JAN DNS.